The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2020 | ALTA-1L: brigatinib vs crizotinib in NSCLC
Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses the ALTA-1L study (NCT02737501) which compares the efficacy and safety of brigatinib to that of crizotinib in ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who have not previously been treated with an ALK inhibitor. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.
